We are live on ! Find out more
RGC icon

Regencell Bioscience
RGC

4 hedge funds and large institutions have $18.9K invested in Regencell Bioscience in 2023 Q1 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 0 closing their positions.

New
Increased
Maintained
Reduced
Closed

33% more funds holding

Funds holding: 3 → 4 (+1)

0% more repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 1

0.13% less ownership

Funds ownership: 0.35% → 0.21% (-0.13%)

42% less capital invested

Capital invested by funds: $32.3K → $18.9K (-$13.4K)

Holders
4
Holders Change
+1
Holders Change %
+33.33%
% of All Funds
0.06%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
1
Reduced
1
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
TRCT
Tower Research Capital (TRC)
New York
+$5.6K
2
Morgan Stanley
Morgan Stanley
New York
+$448

Top Sellers

Rank Fund Capital Flow
1
UBS Group
UBS Group
Switzerland
-$18.7K
Name Holding Trade Value Shares
Change 		Change in
Stake
Morgan Stanley
1
Morgan Stanley
New York
$7.69K +$448 +608 +6%
BlackRock
2
BlackRock
New York
$6.16K – – –
TRCT
3
Tower Research Capital (TRC)
New York
$5K +$5.6K +7,600 New
UBS Group
4
UBS Group
Switzerland
$26 -$18.7K -25,384 -100%

RGC Hedge Fund Activity: Q1 2023 in Review

4 of the 6,276 institutional investors tracked by Wall St. Rank reported a position in Regencell Bioscience (RGC) for Q1 2023, worth a combined $18.9K — down 42% from $32.3K a quarter earlier.

Buyers outnumbered sellers: 1 fund opened new RGC positions and 0 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.

The largest buyer was Tower Research Capital (TRC), opening a new position worth an estimated $5.6K. The largest seller was UBS Group, cutting an estimated $18.7K.

  • 4 institutional investors held Regencell Bioscience (RGC) as of Q1 2023, up from 3 in Q4 2022.
  • Funds reported $18.9K of Regencell Bioscience stock for Q1 2023, down 42% quarter-over-quarter.
  • 1 fund opened new Regencell Bioscience positions in Q1 2023 and 0 closed out, a net change of +1 holder.
  • The largest Regencell Bioscience buyer in Q1 2023 was Tower Research Capital (TRC), an estimated $5.6K added.
  • The largest Regencell Bioscience seller in Q1 2023 was UBS Group, an estimated $18.7K sold.

Based on aggregated 13F filings for Q1 2023.